Medical Research Council – Page 11 – Communicable Diseases Research

Moving singing for lung health online in response to COVID-19: experience from a randomised controlled trial

COVID-19에 대응하여 폐 건강을 위한 온라인 노래 이동: 무작위 대조 시험의 경험

Randomized Controlled Trial

Published on 2020-11-252022-08-09
Journal: BMJ Open Respiratory Research [Category] 임상,

Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform

Articles

Published on 2020-11-052022-10-29
Journal: The Lancet Rheumatology [Category] COVID-19,

[키워드] 95% CI absolute difference acute respiratory syndrome age Analysis association biologic clinical study coronavirus COVID-19 COVID-19 mortality COVID-19 outbreak Cox regression cumulative death deaths disease Effect Effectiveness England epithelial cell Estimated evaluate Evidence finding funding General population geographical region Hydroxychloroquine immunosuppressive drugs in vitro indicated information inhibit Interaction Medical Research Council Model Mortality National negative control Non-COVID-19 Older OpenSAFELY outcome Patient patients with COVID-19 platform population-based cohort prevention of COVID-19 primary care Prophylactic Randomised trial reduced Registered rheumatoid arthritis rheumatological risk of COVID-19 robust SARS-CoV-2 Sex shown systemic lupus erythematosus the disease Treatment use of hydroxychloroquine with COVID-19
[DOI] 10.1016/S2665-9913(20)30378-7 PMC 바로가기 [Article Type] Articles

Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform

Articles

Published on 2020-11-012022-10-29
Journal: The Lancet. Respiratory Medicine [Category] COVID-19, Fulltext, SARS,

[키워드] 95% CI acute respiratory disease acute respiratory syndrome adjusted age analysed Analysis association Asthma calculated category chronic obstructive Cohort combination therapy COPD coronavirus covariates COVID-19 COVID-19 pandemic COVID-19-related death Cox regression model database death description diagnosed disease severity E-value EHR Electronic health record eligible England expected explained finding Follow-up funding hazard ratio Health high-dose ICS hospital HRs ICS ICSs increased risk individual Infection Inhaled inhaled corticosteroid LABA–LAMA LABA–LAMA combination long-acting muscarinic antagonist low-dose Medical Research Council medium dose Observational cohort study Observed office Older OpenSAFELY outcome Patient people with asthma people with COPD platform Prevalence primary care PROTECT pulmonary disease recorded respiratory medication SABA Sex short-acting β agonist smoker Statistics Support were given
[DOI] 10.1016/S2213-2600(20)30415-X PMC 바로가기 [Article Type] Articles

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

COVID-19로 병원에 입원한 환자의 Lopinavir-ritonavir(RECOVERY): 무작위, 통제, 공개, 플랫폼 시험

Randomized Controlled Trial

Published on 2020-10-242022-08-13
Journal: Lancet (London, England) [Category] 임상,

[키워드] 28-day mortality 95% CI active treatment all-cause mortality allocation concealment assigned Azithromycin baseline both groups by mouth composite endpoint death Dexamethasone died discharge discharged eligible finding funding groups hospital Hospital stay Hydroxychloroquine IMPROVE in both groups in vitro activity intention-to-treat basis Invasive mechanical ventilation ISRCTN Lopinavir Lopinavir–ritonavir median Medical Research Council mouth no significant difference observational studies Open-label outcome Participants Patient Platform trial preclinical studies Primary outcome proportion randomisation randomised Randomised trial Randomly rate ratio receive recovery reductions reductions in Registered Result risk risk ratio Ritonavir Standard of care subgroups of patients Support the patient treat Treatment treatment for COVID-19 treatment group Trial usual care web-based simple with COVID-19
[DOI] 10.1016/S0140-6736(20)32013-4 PMC 바로가기 [Article Type] Randomized Controlled Trial

How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis

Infectious Diseases

Published on 2020-10-052022-10-28
Journal: BMJ Open [Category] COVID-19, Fulltext, MERS, SARS,

[키워드] Admitted Patient analysed Analysis biostatistics clinical trial clinical trials Complete Controlled COVID-19 COVID-19 pandemic database declined determine discharge eligibility England enrolled enrolment exclusion feasible First wave FIVE hospitalisation hospitalised hospitalised patient Infection Infectious diseases laboratory-confirmed SARS-CoV-2 infection limit Medical Research Council number objective Observational cohort study ongoing trials outcome measure Palliative care Pandemics participant patient cohort Population proliferation prospective observational study randomisation receiving recovery recruitment Registered required Result setting Standard Study design target Treatment Trial Trial registration trials UK Government unit were excluded with COVID-19
[DOI] 10.1136/bmjopen-2020-044566 PMC 바로가기 [Article Type] Infectious Diseases

Personalised health education against health damage of COVID-19 epidemic in the elderly Hungarian population (PROACTIVE-19): protocol of an adaptive randomised controlled clinical trial

Study Protocol

Published on 2020-09-292022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] adaptive Admission affecting age alcohol approved assessment attenuate boost caused change clinical trial complex concerning condition COVID-19 COVID-19 epidemic detrimental effect Effect ethics committee Follow-up group Health Health Assessment Hospital admission ICU ICU admission incidence include intensive care Intervention lack life-threatening Medical Research Council mental health Mortality nCOV-2019 older population outcome overall mortality pandemic participant personalised pharmacological physical activity Pragmatic prevention primary endpoint protocol public health randomised randomised controlled randomised controlled trial receive reduce Registered Sample size SARS-CoV-2 smoking subject therapy Treatment WHO World Health Organization
[DOI] 10.1186/s13063-020-04733-0 PMC 바로가기 [Article Type] Study Protocol

Acupressure therapy and Liu Zi Jue Qigong for pulmonary function and quality of life in patients with severe novel coronavirus pneumonia (COVID-19): a study protocol for a randomized controlled trial

중증 신종 코로나바이러스 폐렴(COVID-19) 환자의 폐 기능 및 삶의 질을 위한 지압 요법 및 Liu Zi Jue Qigong: 무작위 대조 시험을 위한 연구 프로토콜

Study Protocol

Published on 2020-08-272022-08-13
Journal: Trials [Category] MERS, 임상,

[키워드] 1:1 2019 novel coronavirus activities activity Acupressure Acupressure therapy addition Admission Adverse adverse events analyst assessor-blinded assessment assessments assigned Barthel Index both groups can be used Chinese Chinese Clinical Trial Registry clinical clinical scale clinical scales complementary Controlled trial COVID-19 Daily discharge Dyspnea effective therapy Efficacy evaluate event Evidence evidence of Hospitalization in both group include intervention group Liu Zi Jue Qigong Liu Zi Jue Qigong exercises Medical Research Council Modified Medical Research Council Dyspnea Scale Novel coronavirus parallel-design Patient Patient Health Questionnaire-9 Scale patients with COVID-19 performed Pneumonia poor prognosis Primary outcome Pulmonary function Qigong Qigong exercise Qigong exercises Quality of life Randomized controlled trial randomized trial Randomly receive recorded recruited registry rehabilitation respiratory Respiratory Symptoms Scale safety evaluation scale secondary outcome Secondary outcomes severe COVID-19 severe disease Study protocol supportive care symptomatic TCMR therapy therapy for COVID-19 Traditional Chinese medicine Traditional Chinese medicine rehabilitation Treatment Trial twice a day Two-arm Wuhan Wuhan, China
[DOI] 10.1186/s13063-020-04693-5 PMC 바로가기 [Article Type] Study Protocol

Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study

Articles

Published on 2020-08-212022-10-29
Journal: The Lancet Rheumatology [Category] COVID-19,

[키워드] addition adverse event angina appear authorisation calibrated case sery chest pain cohort study Combination Cox model Denmark Department determine development electronic medical record Emergency use estimate European Federation finding foundation funding Germany hazard ratio heart failure Horizon HRs Hydroxychloroquine hydroxychloroquine plus azithromycin hydroxychloroquine treatment increase increased risk initiative Innovation IQVIA janssen Japan less Medical Research Council Medicine Ministry of Health Mortality negative control Netherlands NIHR Older outcome Oxford partnership Patient patients with COVID-19 pharmaceutical Pneumonia populations Propensity score Research Retrospective study rheumatoid arthritis risk routine care severe adverse event Singapore Spain Stratification sulfasalazine training treat Treatment USA use of hydroxychloroquine veteran Welfare were used
[DOI] 10.1016/S2665-9913(20)30276-9 PMC 바로가기 [Article Type] Articles

Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial

체중이 20kg 이상인 HIV가 있는 소아에 대한 단순 돌루테그라비르 투여: 다기관, 무작위 ODYSSEY 시험의 약동학 및 안전성 하위 연구

Article

Published on 2020-08-042022-09-06
Journal: The Lancet. HIV [Category] Communicable Disease,

[키워드] (coefficient of variation (cryptococcal meningitis Adults adverse event adverse events AIDS approval approved Asymptomatic baseline children coefficient Coefficient of variation Concentration concentration-time curve cryptococcal meningitis dolutegravir dose dosed doses drug enrolled estimate European evaluate evaluated finding follow-up period food foundation funding geometric geometric mean highest HIV less Medical Research Council Meningitis multicentre network neutropenia ODYSSEY once daily Open-label over Patient pharmacokinetic pharmacokinetic data plasma profile randomised reference values regulatory authority reported required Research SRA subject Tablet tablets target the WHO Treatment Trial Uganda Variation was done weighed with HIV Zimbabwe
[DOI] 10.1016/S2352-3018(20)30189-2 PMC 바로가기 [Article Type] Article

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

Randomized Controlled Trial

Published on 2020-07-172022-10-04
Journal: The New England Journal of Medicine [Category] Fulltext, MERS, 임상,